SADI-S metabolic surgery yields sustained weight loss, improved glycemic control, and reduced insulin needs over five years in Type 1 Diabetes
Background
Managing obesity in adults with Type 1 Diabetes Mellitus (T1DM) presents significant challenges, primarily due to the coexistence of insulin dependence and pronounced insulin resistance. While metabolic surgery is a well-established intervention for Type 2 Diabetes, long-term efficacy and safety data for its application in T1DM populations remain limited. This study addresses this gap by evaluating the five-year outcomes of single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) in this specific patient group, aiming to understand its physiological impact.
Study Design
This single-center, observational cohort study followed 8 adults diagnosed with Type 1 Diabetes Mellitus and obesity who underwent primary single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S). Patients were monitored for up to five years post-procedure. Primary outcomes included changes in weight, BMI, HbA1c levels, total daily insulin requirements, and continuous glucose monitoring (CGM) metrics. Nutritional status, peri-operative safety, and patient-reported quality-of-life measures, including the SF-12, Diabetes Treatment Satisfaction Questionnaire, and BAROS, were also assessed.
Results
Over five years, patients demonstrated significant and sustained improvements. Mean BMI decreased from 38.6 kg/m² to 26.4 kg/m². HbA1c levels improved from a baseline of 8.4% to 7.1%. Total daily insulin requirements were substantially reduced, decreasing by approximately 45%. CGM data revealed an increased time in range, alongside reduced glycemic variability, while maintaining stable rates of hypoglycemia. Quality-of-life scores showed improvement across all validated domains. Safety analysis noted two cases of early postoperative euglycemic diabetic ketoacidosis, which occurred before the implementation of extended inpatient monitoring protocols; no further cases were observed thereafter. Importantly, no patient developed protein-calorie malnutrition or severe micronutrient deficiencies, indicating acceptable nutritional outcomes.
SADI-S led to a significant reduction in total daily insulin requirements by approximately 45% over five years in T1DM patients.
Key Findings
- Mean BMI decreased from 38.6 kg/m² to 26.4 kg/m² over five years.
HbA1clevels improved from 8.4% to 7.1%.- Total daily insulin requirements decreased by approximately 45%.
CGMdata showed increased time in range and reduced glycemic variability.- No patient developed protein-calorie malnutrition or severe micronutrient deficiency.
Why It Matters
This study provides compelling long-term evidence that SADI-S is a viable and physiologically favorable metabolic procedure for carefully selected adults with Type 1 Diabetes and obesity. The sustained weight loss, improved glycemic stability, and substantial reduction in insulin requirements suggest a significant shift in managing this complex patient population. For clinicians and patients, this opens a new avenue beyond conventional medical management, potentially improving quality of life and reducing the burden of insulin therapy. While a surgical procedure, the data supports considering SADI-S as a powerful tool in the metabolic toolkit, offering a durable solution where medical therapies often fall short. The acceptable nutritional outcomes further bolster its potential for broader clinical translation.
sadi-s
type-1-diabetes
obesity
metabolic-surgery
weight-loss
glycemic-control